Hepatic Impairment Clinical Trials

25 recruitingLast updated: June 18, 2026

There are 25 actively recruiting hepatic impairment clinical trials across 10 countries. Studies span Phase 1. Top locations include San Antonio, Texas, United States, Orlando, Florida, United States, Miami, Florida, United States. Updated daily from ClinicalTrials.gov.


Hepatic Impairment Trials at a Glance

25 actively recruiting trials for hepatic impairment are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 1 with 25 trials, with the heaviest enrollment activity in San Antonio, Orlando, and Miami. Lead sponsors running hepatic impairment studies include AstraZeneca, Boehringer Ingelheim, and Merck Sharp & Dohme LLC.

Browse hepatic impairment trials by phase

Treatments under study

About Hepatic Impairment Clinical Trials

Looking for clinical trials for Hepatic Impairment? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatic Impairment trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatic Impairment clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting
Phase 1

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

Healthy VolunteersHepatic Impairment
Bristol-Myers Squibb24 enrolled3 locationsNCT07248839
Recruiting
Phase 1

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

HealthyHepatic Impairment
Boehringer Ingelheim32 enrolled3 locationsNCT07023354
Recruiting
Phase 1

Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment

Advanced Malignancies and Hepatic Impairment
Novartis Pharmaceuticals24 enrolled5 locationsNCT07422610
Recruiting
Phase 1

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

Hepatic Impairment
Genentech, Inc.32 enrolled4 locationsNCT07144111
Recruiting
Phase 1

Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants

Severe Hepatic ImpairmentNormal Hepatic Function
Institut de Recherches Internationales Servier (I.R.I.S.)20 enrolled3 locationsNCT07250633
Recruiting
Phase 1

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Hepatic Impairment
AstraZeneca28 enrolled4 locationsNCT07546760
Recruiting
Phase 1

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function

HealthyHepatic Impairment
Pfizer26 enrolled3 locationsNCT07269301
Recruiting
Phase 1

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Moderate Hepatic Impairment
AstraZeneca20 enrolled2 locationsNCT07343960
Recruiting
Phase 1

A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems

HealthyHepatic Impairment
Boehringer Ingelheim44 enrolled1 locationNCT07486102
Recruiting
Phase 1

Radiprodil in Participants With Hepatic Impairment

Hepatic Impairment
GRIN Therapeutics, Inc.40 enrolled2 locationsNCT07457229
Recruiting
Phase 1

Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

HealthyHepatic Impairment
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany32 enrolled3 locationsNCT06997276
Recruiting
Phase 1

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Healthy Volunteer StudyRenal ImpairmentHepatic Impairment
Atea Pharmaceuticals, Inc.28 enrolled2 locationsNCT06911320
Recruiting
Phase 1

Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment

Hepatic Impairment
Daiichi Sankyo12 enrolled3 locationsNCT06740799
Recruiting
Phase 1

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

Hepatic Impairment (HI)
Edgewise Therapeutics, Inc.32 enrolled2 locationsNCT07324616
Recruiting
Phase 1

A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)

HealthyHepatic Impairment
Merck Sharp & Dohme LLC58 enrolled3 locationsNCT07219550
Recruiting
Phase 1

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

CirrhosisCholestatic Liver DiseaseHepatic Impairment
Zydus Therapeutics Inc.30 enrolled1 locationNCT05045482
Recruiting
Phase 1

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

Hepatic Impairment (HI)
Merck Sharp & Dohme LLC32 enrolled3 locationsNCT06442436
Recruiting
Phase 1

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Advanced Malignant Solid TumorHepatic Impairment
Epizyme, Inc.24 enrolled18 locationsNCT04241835
Recruiting
Phase 1

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment
Eisai Co., Ltd.18 enrolled8 locationsNCT04271488
Recruiting
Phase 1

A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment

Patients With Mild or Moderate Hepatic Impairment
Taisho Pharmaceutical Co., Ltd.24 enrolled1 locationNCT07231029